JW Lifescience Corporation (KRX:234080)

Market Cap	164.14B
Revenue (ttm)	221.32B
Net Income (ttm)	28.82B
Shares Out	15.48M
EPS (ttm)	1,860.99
PE Ratio	5.70
Forward PE	n/a
Dividend	500.00 (4.72%)
Ex-Dividend Date	Dec 27, 2024

Volume	80
Average Volume	27,187
Open	10,500
Previous Close	10,390
Day's Range	10,430 - 10,500
52-Week Range	10,000 - 13,550
Beta	0.59
RSI	50.05
Earnings Date	Feb 5, 2025

About JW Lifescience

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 301
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 234080

Financial Performance

In 2023, JW Lifescience's revenue was 206.86 billion, an increase of 9.49% compared to the previous year's 188.93 billion. Earnings were 28.14 billion, an increase of 88.11%.